MLYS250117P12500
- 1.70
- 0.000.00%
Mineralys Therapeutics Newsroom
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell
Strategic Advancements and FDA Clearance Propel Mineralys Therapeutics to a Buy Rating
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials
Express News | Mineralys Therapeutics Inc - Primary Outcome Measure Is Change in Apnea-Hypopnea Episodes
Express News | Mineralys Therapeutics Inc - to Initiate Phase 2 Trial in Q1 2025
Express News | Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients With Hypertension
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Mineralys Therapeutics | 8-K: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics | 10-Q: Q3 2024 Earnings Report
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $26
Buy Rating on Mineralys Therapeutics Driven by Lorundrostat's Potential in Hypertension Treatment
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript Summary
Mineralys Therapeutics Q3 2024 GAAP EPS $(1.13) Misses $(0.83) Estimate
Express News | Mineralys Therapeutics Q3 Operating Income USD -60.106 Million
Earnings Scheduled For November 11, 2024
Insights Into Mineralys Therapeutics's Upcoming Earnings
Earnings Preview: MLYS to Report Financial Results Post-market on November 11
$Mineralys Therapeutics(MLYS.US)$ is scheduled to release its financial results post-market on November 11 ET. Earnings PreviewAnalysts estimate $Mineralys Therapeutics(MLYS.US)$ to post revenue of
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024